ERBB2 and gastric cancer: To test this possibility, we established three new HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2 and GLM-4) derived from liver metastasis (Nakanishi et al, 2005) and examined the sensitivity of these cell lines to gefitinib.